CMB.TECH announces final year results CMB.TECH ANNOUNCES FINAL YEAR RESULTS ANTWERP, Belgium, 31 March 2026 – CMB.TECH NV (“CMBT”, “CMB.TECH” of “the company” (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) reported its final financial results today for the full year ended 31 December 2025. HIGHLIGHTS 2025 Financial highlights: Profit of USD 89.1 million in Q4 2025 bringing full year profit to USD 139.1 million No major changes compared to the preliminary figures published on 26/2/26Total contract backlog increased to USD 3.05 billion Fleet highlights: CMB.TECH f...
Autolus reported FY25 results in line with expectations with Aucatzyl sales amounting to $ 74.3m, in line with CSS. Management re-iterated FY26 guidance of $ 120-$ 135m in Aucatzyl sales (includes US and UK revenue), which we think is within reach (KBCSe FY26: $ 146.5m) given the strong initial demand and positive real world experience as demonstrated by the ROCCA dataset. In the pipeline, phase 1 data for Aucatzyl in progressive MS by YE26 could provide upside and pique interest from potential ...
Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates AUCATZYL® (obecabtagene autoleucel) net product revenue of $23.3 million* for the fourth quarter of 2025 and $74.3 million* for the full year of 2025AUCATZYL® UK launch underway following successful National Institute for Health and Care Excellence (NICE) evaluationAutolus continues to expect full year 2026 AUCATZYL® net product revenue of $120 million to $135 million and shift to positive gross margin to occur in 2026Independent real-world AUCATZYL® data from ROCCA consortium confirm high...
In this ING equities impact assessment of the situation in the Middle East report, we focus on a selection of 11 companies which we cover and we expect to be impacted by the current situation in the Middle East following the war in Iran, which started on 28 February and has since spread further into the region. We found that every company in this report faces its own challenges in the short term, while we also discuss the longer-term strategic implications.
Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026 LONDON and GAITHERSBURG, Md., March 16, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that the Company will release its fourth quarter and full year 2025 financial results and operational highlights before open of U.S. markets on Friday, March 27, 2026. Management will host a conference call and webc...
ASM publishes Annual Report 2025 Almere, The NetherlandsMarch 12, 2026, 5.45 p.m. CET ASM International N.V. (Euronext Amsterdam: ASM) today publishes its Annual Report 2025 ASM's Annual Report 2025 is available in ESEF reporting package and as a PDF file on the company's website . ASM publishes the Annual Report in accordance with European Single Electronic Format (ESEF) reporting requirements. In line with the ESEF requirements, the primary consolidated financial statements have been labelled with XBRL tags. ASM will hold its Annual General Meeting (AGM) on May 11, 2026. The AGM age...
Today, we are publishing the Semicap Equipment section of our 30th Tech Infrastructure Quarterly Bible. The Tech Bible is a must-read for any tech investor, as it summarizes the quarterly earnings reports from the over 140 companies we track, providing an update on our key perspectives and convictions. In the coming weeks we will publish sections on Automotive, Hyperscale & Cloud, Telecom Equipment, PCs, Enterprise IT, and Foundry. 4Q25 semicap revenues increased 9% QoQ led by DRAM, while China...
ASM provided a very solid guidance for FY26. We expect this strength to continue in subsequent years as AI strength and ongoing technology transitions are key tailwinds for ASM. We expect the company to significantly outgrow its peers. We again increase our estimates, up our DCF-based target price to €950 per share (from €900) and reiterate our BUY. ASM remains on the ING Benelux Favourites list.
We provide more colour in this note on our change in TP and recommendation following ASMi FY25 results, which were good given the improved outlook. We see upside on the FY26 estimates, yet expectations for FY27 are already high and leave little room for upside, while the valuation is also above the historical average. We derive a fair value of €658 p.s. based on our FY27 diluted EPS of € 22.1 and a PE multiple of 30x. Given the downside we reduced our recommendation this morning from Accumulate ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.